High doses of trospium chloride in patients with idiopathic overactive bladder. Data of large-scale, multicenter observational program “Resource”


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Purpose. Evaluation of the efficacy and safety of different doses of trospium chloride in patients with idiopathic overactive bladder. Materials and Methods. Large-scale observational program «Resource» included 669 patients with idiopathic OAB - 359 women and 310 men. At the first visit, all patients were assigned to use of trospium chloride at a standard dose of 45 mg per day. The results of treatment were evaluated during follow-up visits at 3, 6, 9 and 12 weeks. Depending on the results of examination, the dose was reduced in the presence of adverse events and increased in case of insufficient treatment effects. Results. After 12 weeks, 102 patients have been receiving the drug at a dose of 30 mg/day, 241 - at a dose of 45 mg/day, 257 - at a dose of 60 mg/ day, and 22 - at a dose of 75 mg/day. Conclusions. Individual approach to the selection of doses of trospium chloride in patients with idiopathic OAB can be quite effective and safe measure to achieve optimal clinical outcome with a good safety profile.

Full Text

Restricted Access

About the authors

G. G Krivoborodov

RNSMU n.a. N.I. Pirogov

Email: Dr.krivoborodov@yandex.ru
Department of Faculty Surgery, Urology (Head - A.I. Kirienko, Academician of RAS, Professor) of the Medical Faculty

E. I Tur

RNSMU n.a. N.I. Pirogov

Email: amadeymozart@yandex.ru
Department of Faculty Surgery, Urology (Head - A.I. Kirienko, Academician of RAS, Professor) of the Medical Faculty

N. S Efremov

RNSMU n.a. N.I. Pirogov

Email: nefr@yandex.ru
Department of Faculty Surgery, Urology (Head - A.I. Kirienko, Academician of RAS, Professor) of the Medical Faculty

M. E Shkolnikov

RNSMU n.a. N.I. Pirogov

Department of Faculty Surgery, Urology (Head - A.I. Kirienko, Academician of RAS, Professor) of the Medical Faculty

References

  1. Kinsey D., Pretorius S., Glover L., Alexander T. The psychological impact of overactive bladder: A systematic review. J Health Psychol. 2016;21(1):69-81.
  2. Wagg A., Compion G., Fahey A., Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767-1774.
  3. Menarini M., Del Popolo G., Di Benedetto P., Haselmann J., Bödeker R.H., Schwantes U., Madersbacher H. TcP128-Study Group. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther. 2006; 44(12): 623-632.
  4. Coyne K.S., Sexton C.C., Vats V., Thompson C., Kopp Z.S., Milsom I. National community prevalence of overactive bladder in the United States strati ed by sex and age. Urology. 2011;77(5):1081-1087.
  5. Reeves Р., Irwin D., Kelleher C., Milsom I., Kopp Z., Calvert N., Lloyd A. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006;50(5):1050-1057.
  6. Karsenty G., Baverstock R., Carlson K., Diaz D.C., Cruz F., Dmochowski R., Fulford S., Giannantoni A., Heesakkers J., Kaufmann A., Peyrat L., Thavaseelan J., Dasgupta P. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract. 2014;68(6):731-742.
  7. Burkhard F.C., Ucas M.G., Berghmans L.C. et al. Urinary incontinence. EAU guidelines 2015.
  8. McDonagh et al. Drug class review: agents for overactive bladder. Final report Update 4. Portland (OR): Oregon Health & Science University; 2009 Drug Class Reviews.
  9. Nitti V.W., Dmochowski R., Herschorn S., Sand P., Thompson C., Nardo C., Yan X., Haag-Molkenteller C. EMBARK Study Group. Onabotulinumtoxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186-2193.
  10. Chapple C.R., Kaplan S.A., Mitcheson D., Klecka J., Cummings J., Drogendijk T., Dorrepaal C., Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296-305.
  11. Chapple C.R., Cardozo L., Nitti V.W., Siddiqui E., Michel M.C. Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014 33(1):17-30.
  12. Chancellor M., Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2): 167-174.
  13. Doroshyenko O., Jetter A., Odenthal K.P., Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701-720.
  14. Biastre K., Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009;43(2): 283-295.
  15. McDonagh et al. Drug class review: agents for overactive bladder. Final report. Update 4. 2009, Oregon Health & Science University: Portland, Oregon.
  16. Novara G., Galfano A., Secco S., D’Elia C., Cavalleri S., Ficarra V., Artibani W. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740-763.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies